SCHEMBL25613439

CNc1ncnc2c1ncn2[C@@H]1C2C[C@@]2(COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1OCNc1ncnc2c1ncn2[C@H]1[C@H](OCNc2ncnc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@]3(CO)CC[C@H]23)[C@H](O)[C@]2(COP(=O)(O)O)CC[C@H]12

nearest known ligand 0.70

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	P2RY1	P47900	13/20	0.70

▸	P2RY2	P41231	5/20	0.70

▸	P2RY11	Q96G91	1/20	0.55

▸	ADORA3	P0DMS8	3/20	0.47

▸	ADORA1	P30542	2/20	0.47

▸	HTR2C	P28335	1/20	0.43

▸	HTR2B	P41595	1/20	0.43

▸	TMEM97	Q5BJF2	1/20	0.43

▸	SIGMAR1	Q99720	1/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19807530	0.97	P2RY1 (0.65)	P2RY1P2RY2P2RY11ADORA3ADORA1
SCHEMBL26934782	0.94	P2RY1 (0.62)	P2RY1P2RY2P2RY11ADORA3ADORA1
SCHEMBL19464968	0.94	P2RY1 (0.58)	P2RY1P2RY2P2RY11ADORA3ADORA1
SCHEMBL22937443	0.86	P2RY1 (0.76)	P2RY1P2RY2P2RY11ADORA3ADORA1
SCHEMBL19464971	0.86	P2RY1 (0.83)	P2RY1P2RY2P2RY11ADORA3ADORA1
SCHEMBL19807529	0.85	P2RY1 (0.84)	P2RY1P2RY2P2RY11ADORA3
SCHEMBL21710863	0.84	P2RY1 (0.98)	P2RY1P2RY2P2RY11ADORA3
SCHEMBL26934770	0.84	P2RY1 (0.98)	P2RY1P2RY2P2RY11ADORA3
SCHEMBL26934769	0.84	P2RY1 (1.00)	P2RY1P2RY2P2RY11ADORA3
SCHEMBL19503289	0.81	P2RY1 (0.85)	P2RY1P2RY2P2RY11ADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230165887-A1	COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS	THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	2023-06-01	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230165887-A1	COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS	TNNI3, CPT1B, TNNT2	P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.